CA
MIST icon

Cliff Asness’s Milestone Pharmaceuticals MIST Stock Holding History

Cliff Asness’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$20.2K – 3798
2025
Q4 		$20.2K Hold
10,000
– – ﹤0.01% 3548
2025
Q3 		$20K Buy
+10,000
New +$17.6K ﹤0.01% 3448

Other funds holding MIST

PCM
Pavaki Capital Management Pueblo, Colorado $287M AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Cliff Asness's MIST Position: Q1 2026 in Review

Cliff Asness sold out of Milestone Pharmaceuticals (MIST) in Q1 2026, closing a stake of 10,000 shares — an estimated $20.2K sold.

Cliff Asness first reported a position in MIST in Q3 2025 and held it in 2 quarters. The position peaked at $20.2K in Q4 2025. 87 funds tracked by Wall St. Rank hold MIST as of Q1 2026.

  • Cliff Asness reported no remaining Milestone Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Cliff Asness sold 10,000 Milestone Pharmaceuticals shares in Q1 2026, an estimated $20.2K.
  • Cliff Asness first reported a position in Milestone Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Cliff Asness's Milestone Pharmaceuticals position peaked at $20.2K in Q4 2025.
  • 87 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.